Venetoclax plus cyclophosphamide and cytarabine as induction regimen for adult acute myeloid leukemia.
acute myeloid leukemia
cyclophosphamide
cytarabine
induction chemotherapy
venetoclax
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
25
03
2023
accepted:
24
04
2023
medline:
5
6
2023
pubmed:
5
6
2023
entrez:
5
6
2023
Statut:
epublish
Résumé
The efficacy of induction chemotherapy (IC) for acute myeloid leukemia (AML) has improved significantly with the application of targeting drugs. Our previous study showed that a 4-day IC regimen of cyclophosphamide (CTX) and Ara-C [CA (4 + 3)] achieved similar complete remission (CR) rate (80%) compared with the traditional 7-day regimen, and the survival rate appeared to be better. In this pilot study, we further shortened the CA regimen to 3 days, added low-dose venetoclax (VEN, 200 mg/day) (VCA), and reported the efficacy and safety here. Twenty-five newly diagnosed adult AML patients were enrolled in this study and evaluated for the remission rate after one cycle of the VCA regimen. The CR/Cri was 92%, and all these patients had undetectable minimal residual disease (MRD This study showed that the 3-day CTX and Ara-C regimen is highly effective in newly diagnosed AML patients, and the addition of VEN to the CA regimen achieves higher and deeper one-course remission.
Sections du résumé
Background
UNASSIGNED
The efficacy of induction chemotherapy (IC) for acute myeloid leukemia (AML) has improved significantly with the application of targeting drugs. Our previous study showed that a 4-day IC regimen of cyclophosphamide (CTX) and Ara-C [CA (4 + 3)] achieved similar complete remission (CR) rate (80%) compared with the traditional 7-day regimen, and the survival rate appeared to be better.
Methods
UNASSIGNED
In this pilot study, we further shortened the CA regimen to 3 days, added low-dose venetoclax (VEN, 200 mg/day) (VCA), and reported the efficacy and safety here.
Results
UNASSIGNED
Twenty-five newly diagnosed adult AML patients were enrolled in this study and evaluated for the remission rate after one cycle of the VCA regimen. The CR/Cri was 92%, and all these patients had undetectable minimal residual disease (MRD
Conclusions
UNASSIGNED
This study showed that the 3-day CTX and Ara-C regimen is highly effective in newly diagnosed AML patients, and the addition of VEN to the CA regimen achieves higher and deeper one-course remission.
Identifiants
pubmed: 37274294
doi: 10.3389/fonc.2023.1193874
pmc: PMC10235496
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1193874Informations de copyright
Copyright © 2023 Zhang, Liu, Li, Hu, Zhao, Huang, Li and Wang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Clin Oncol. 2021 Sep 1;39(25):2768-2778
pubmed: 34043428
Blood. 2015 Jun 18;125(25):3878-85
pubmed: 25833957
Cell Death Differ. 2018 Jan;25(1):56-64
pubmed: 29077093
Blood. 2011 Oct 6;118(14):3832-41
pubmed: 21828126
Blood. 2020 Jun 11;135(24):2137-2145
pubmed: 32219442
Lancet Haematol. 2022 Jun;9(6):e415-e424
pubmed: 35512726
Ann Hematol. 2015 Sep;94(9):1485-92
pubmed: 25944346
J Clin Oncol. 2020 Oct 20;38(30):3506-3517
pubmed: 32687450
JAMA Oncol. 2020 Dec 01;6(12):1890-1899
pubmed: 33030517
J Clin Oncol. 2003 Dec 15;21(24):4642-9
pubmed: 14673054
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
EJHaem. 2020 Aug 11;1(1):79-85
pubmed: 35847688
J Clin Oncol. 2014 Jan 20;32(3):219-28
pubmed: 24297940
N Engl J Med. 2020 Aug 13;383(7):617-629
pubmed: 32786187
Blood Adv. 2021 Dec 28;5(24):5565-5573
pubmed: 34610123
Cancers (Basel). 2022 Mar 01;14(5):
pubmed: 35267586
Blood Adv. 2019 Apr 9;3(7):1103-1117
pubmed: 30948365
Lancet Haematol. 2021 Aug;8(8):e552-e561
pubmed: 34329576
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
N Engl J Med. 2011 May 12;364(19):1844-54
pubmed: 21561350
Curr Opin Hematol. 2022 Mar 1;29(2):63-73
pubmed: 34966123